|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-11-16
|
|
pubmed:abstractText |
Epothilone compounds (e.g. epothilones A and B) represent a new structural class of microtubule inhibitors with the remarkable ability to inhibit tumor growth of multidrug-resistant cell lines at low nanomolar or even subnanomolar concentrations. Unfortunately, this therapeutic efficacy has only been achieved to date with a narrow therapeutic window. Hence, other structural analogs of compounds such as epothilone B are currently being synthesized in the hope that they will demonstrate equivalent antitumor efficacy with reduced systemic toxicity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
pubmed-author:CabralFF,
pubmed-author:FinlayVV,
pubmed-author:JogN VNV,
pubmed-author:LogothetisC JCJ,
pubmed-author:NavoneN MNM,
pubmed-author:NewmanR ARA,
pubmed-author:NicolaouK CKC,
pubmed-author:RaymondMM,
pubmed-author:StephensL CLC,
pubmed-author:TroncosoPP,
pubmed-author:VourloumisDD,
pubmed-author:YangJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
319-26
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11710633-Animals,
pubmed-meshheading:11710633-Antineoplastic Agents,
pubmed-meshheading:11710633-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:11710633-Dose-Response Relationship, Drug,
pubmed-meshheading:11710633-Drug Screening Assays, Antitumor,
pubmed-meshheading:11710633-Epothilones,
pubmed-meshheading:11710633-Humans,
pubmed-meshheading:11710633-Infusions, Intravenous,
pubmed-meshheading:11710633-Macrolides,
pubmed-meshheading:11710633-Male,
pubmed-meshheading:11710633-Mice,
pubmed-meshheading:11710633-Mice, Nude,
pubmed-meshheading:11710633-Paclitaxel,
pubmed-meshheading:11710633-Prostatic Neoplasms,
pubmed-meshheading:11710633-Transplantation, Heterologous,
pubmed-meshheading:11710633-Tumor Cells, Cultured
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts.
|
|
pubmed:affiliation |
Pharmaceutical Development Center, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
